Completed PHASE2 INTERVENTIONAL NCT00047476

D-MPH in the Treatment of Fatigue and Neurobehavioral Function Related to Chemotherapy in Adult Cancer Patients

Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of d-MPH in the Treatment of Fatigue and Neurobehavioral Impairment Related to Chemotherapy in Adult Cancer Patients

Sponsor: Celgene Corporation

Conditions Fatigue Neoplasms

Interventions dexmethylphenidate(d-mph)

Updated 5 times since 2017 Last updated: Jun 23, 2005 Started: Jun 30, 2002 Completion: Mar 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Fatigue and Neoplasms, this trial is completed. The trial is conducted by Celgene Corporation and has accumulated 5 data snapshots since 2002. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jun 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Celgene Corporation

Data source: Celgene

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Baltimore, United States , Berkeley, United States , Birmingham, United States , Boca Raton, United States , Flagstaff, United States , Greenbrae, United States , Greenville, United States , Lexington, United States , Madison, United States and 10 more locations